Evidence map›Paper›PMID 24241962›Full record

ArticleInternational journal of hematology2013

Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.

Masakatsu Yanagimachi, Hiroaki Goto, Tetsuji Kaneko, Takuya Naruto, Koji Sasaki, Masanobu Takeuchi, Reo Tanoshima, Hiromi Kato, Tomoko Yokosuka, Ryosuke Kajiwara and 7 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02011022 (Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02011022 nacompletednot on this map

Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Significant Impact Factors and Establishment of a Clinically Relevant Model

TypeinterventionalSponsorThe Children's Hospital of Zhejiang University School of MedicineRan2009 to 2010Enrolled291ConditionsMethotrexate Adverse ReactionArms3g MTX, 5g MTX
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. [Association ofZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  5. Fluid Stewardship of Maintenance Intravenous Fluids.Journal of pharmacy practice · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Masakatsu YanagimachiDepartment of Pediatrics, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan, myanagi@yokohama-cu.ac.jp.
Hiroaki Goto
Tetsuji Kaneko
Takuya Naruto
Koji Sasaki
Masanobu Takeuchi
Reo Tanoshima
Hiromi Kato
Tomoko Yokosuka
Ryosuke Kajiwara
Hisaki Fujii
Fumiko Tanaka
Shoko Goto
Hiroyuki Takahashi
Masaaki Mori
Sumio Kai
Shumpei Yokota

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-dose methotrexate therapy (HD-MTX) has been well established for the treatment of childhood acute lymphoblastic leukemia (ALL). The aims of this study were to investigate whether clinical and pharmacogenetic factors influence plasma MTX concentration and renal dysfunction in patients treated with HD-MTX. In a total of 127 courses of HD-MTX in 51 patients with childhood ALL, influence of clinical and pharmacogenetic factors on plasma MTX concentration and HD-MTX-related renal dysfunction was evaluated. Clinical factors included age, gender, duration of HD-MTX continuous-infusion and duration of pre-hydration before HD-MTX. Pharmacogenetic factors included 5 gene polymorphisms within the MTX pathway genes, namely, SLC19A1, MTHFR, ABCC2 and ABCG2. Short duration of pre-hydration before HD-MTX is the most important risk factor for prolonged high MTX concentration (p < 0.001, OR 6.40, 95 % CI 2.39-17.16) and renal dysfunction (p = 0.013, OR 3.15, 95 % CI 1.27-7.80). The T allele at MTHFR C677T was the risk factor for prolonged high MTX concentration (p = 0.009, OR 5.54, 95 % CI 1.54-19.85), but not for renal dysfunction. We found the influence of MTHFR C677T polymorphism on prolonged high MTX concentration. We reconfirmed the importance of adequate pre-hydration before HD-MTX to prevent prolonged high MTX concentration and MTX-related renal dysfunction.

Indexed as

PharmacogeneticsAdolescentAntimetabolites, AntineoplasticChildChild, PreschoolFemaleHumansInfantInfusions, IntravenousKidneyMaleMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)Multidrug Resistance-Associated Protein 2Odds RatioPolymorphism, Single NucleotideABCC2 protein, humanAntimetabolites, AntineoplasticMethotrexateMethylenetetrahydrofolate Reductase (NADPH2)Multidrug Resistance-Associated Protein 2

Identifiers

PMID24241962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.